Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive ResultsAccesswire • 04/14/22
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4Accesswire • 12/29/21
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2Accesswire • 12/08/21
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and DiabetesAccesswire • 11/10/21
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription CannabidiolAccesswire • 11/01/21
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceAccesswire • 09/09/21